Meanwhile, Tyro3 promotes the development of the original tumor microenvironment by inhibiting ferroptosis of tumor cells induced by anti-PD-1/PD-L1 and reducing the M1/M2 macrophage ratio, thus leading to resistance to PD-1/PD-L1 therapy [43]. This evidence concerns the gene TYRO3 and neoplasm.